Apimeds Pharmaceuticals US, Inc. (APUS) vs Sunshine Biopharma, Inc. (SBFM)

Apimeds Pharmaceuticals US, Inc. and Sunshine Biopharma, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $7.6M against $3.3M — 2.3× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −16.5%) and the higher return on invested capital (−16.0% vs −26.7%). Across the 13 metrics below, Apimeds Pharmaceuticals US, Inc. leads on 7 and Sunshine Biopharma, Inc. on 6.

Valuation

Metric APUS SBFM Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S n/m 0.03 2.25
P/B 0.12 0.04 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 2.48 12.29
EV/Sales n/m (0.34) 2.56
Earnings yield (504.41%) (1,208.33%) (2.99%)
Free cash flow yield (107.35%) (482.76%) 0.00%

Profitability

Metric APUS SBFM Drug Manufacturers Specialty & Generic median
Gross margin — 30.30% 53.94%
Operating margin 0.00% (16.65%) 0.00%
Net margin 0.00% (16.50%) 0.00%
Free cash flow margin 0.00% (15.66%) 0.00%
Return on equity (100.13%) (21.93%) (0.40%)
Return on assets (84.20%) (17.78%) (3.32%)
Return on invested capital (15.96%) (26.67%) 0.00%

Growth

Metric APUS SBFM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — (2.74%) 10.01%
EPS growth (last fiscal year) (205.56%) 80.33% —
Revenue growth, 5-year CAGR — 247.74% 6.74%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS SBFM Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.00 0.05
Current ratio 0.51 5.46 2.31
Net debt to EBITDA 0.38 2.20 0.85

Dividend

Metric APUS SBFM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric APUS SBFM Drug Manufacturers Specialty & Generic median
Market cap 7.59m 3.25m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack